#United States #New York #Pomerantz LLP #Keros Therapeutics #KROS

Investor Alert: Investigating Keros Therapeutics, Inc.

In a crucial development for investors, the Pomerantz Law Firm has initiated an investigation into Keros Therapeutics, Inc. (NASDAQ: KROS) due to potential claims of securities fraud and unlawful business practices. This probe comes in light of recent unsettling announcements from the company that have significantly impacted its stock prices, causing considerable concern among shareholders.

On December 12, 2024, Keros made headlines by issuing a press release that revealed a voluntary halt in dosing during two treatment arms of its ongoing TROPOS trial, which focuses on the therapeutic drug cibotercept (KER-012) for patients suffering from pulmonary arterial hypertension (PAH). The company cited a safety review tied to the unexpected occurrence of adverse events, specifically pericardial effusion. This announcement led to a staggering decline in the company’s share price, plummeting by 73.15%, closing at $18.43 by the end of that trading day.

As if that wasn't enough, on January 15, 2025, Keros unveiled another alarming update, declaring a complete suspension of all dosing activities in the TROPOS trial. This included the treatment arms that involved lower dosages and a placebo, marking a significant shift in their clinical trial progression. Following this news, the stock experienced further depreciation, with a drop of 16.51% to close at $10.42 per share. Investors were left grappling with these overwhelming developments, raising questions about the company’s management and potential lapses in investor communication.

Pomerantz LLP, renowned for its prowess in securities class action litigation, is reaching out to affected investors to gather information on their experiences and assess the possibility of filing a class action lawsuit. The firm has a rich history in representing the rights of shareholders impacted by corporate misconduct, led by the late Abraham L. Pomerantz, a pioneer in this realm. The firm’s record includes recovering substantial damages for affected investors, solidifying its reputation in the legal community.

Interested investors are encouraged to connect with attorney Danielle Peyton at Pomerantz LLP to discuss potential legal actions and explore their options moving forward. This represents a pivotal moment, not only for Keros Therapeutics but also for the involved investors who are now seeking justice for their losses. As such events unfold, the focus will remain on the actions taken by Keros’s board and whether they properly adhered to regulatory and corporate governance norms.

As shareholders await further developments and decisions regarding the actions of Keros Therapeutics, it is imperative for investors to monitor the situation closely, especially considering the grave implications these allegations could have on the company’s future.

The investigation's findings may have broader implications for corporate governance practices and investor rights, underlining the importance of transparency and accountability in the pharmaceutical industry.